13Jun/19

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure – GlobeNewswire

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure  GlobeNewswire

Regulated Information – Inside Information. Treatment with ALLOB resulted in significant clinical and radiological improvements; Treatment with ALLOB was …